Breast Cancer Trial, Recruiting NCT06700382 Sponsor: Shu Wang Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06700382
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with triple negative breast cancer through a biopsy at Peking University People's Hospital.
  • People whose cancer was at a stage that had not spread to distant parts of the body before treatment began (stages T1–T4, N0–N3, M0).
  • People who received their treatment and surgery at Peking University People's Hospital and have hospital records there.
  • People who received chemotherapy before surgery (neoadjuvant chemotherapy), with any number of cycles, and immunotherapy before and/or after surgery is also permitted.
  • People whose post-surgery pathology results confirmed that some cancer cells remained in the breast and/or underarm lymph nodes after treatment.
  • People who have signed an agreement to take part in the Peking University People's Hospital breast disease cohort study.

Who may not be able to join:

  • People whose medical records are incomplete, such as missing imaging scans or pathology reports.
  • People whose breast cancer has spread to other parts of the body (metastatic), or who have cancer in both breasts.
  • People who did not undergo full (radical) surgery to remove the cancer.
  • People who have a harmful or likely harmful change (mutation) in the BRCA gene and who received treatment with PARP inhibitor medications after surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 86+13671287670

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shu Wang
Registry
ClinicalTrials.gov
Start date
1 January 2019
Est. completion
31 December 2031

Where this trial is recruiting

🇨🇳 China

Primary endpoints

disease free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov